Exelixis, Inc. (NASDAQ:EXEL) Q3 2025 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and welcome to the Exelixis' Third Quarter 2025 Financial Results Conference Call. My name is Sherry, and I'll be your operator for today.
Exelixis Inc. (EXEL)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Farallon Capital Thomas Steyer | 19,501,500 | $805,411,950 | +22% | 3.3% |
| 2. | Renaissance Technologies Jim Simons | 15,459,266 | $638,467,686 | -3% | 0.84% |
| 3. | AQR Capital Management Cliff Asness | 9,181,359 | $379,190,107 | +21% | 0.24% |
| 4. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 5,267,941 | $217,565,963 | +1% | 0.14% |
| 5. | Caligan Partners David Johnson | 1,525,730 | $63,012,649 | 8.25% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $43.12 | 27,532 | $1,187,234.90 | 1,553,262 | 2025-11-25 | Filing | |
| $20.76 | 225,000 | $4,670,055.00 | 1,525,730 | 2024-05-30 | Filing | |
| $20.32 | 200,000 | $4,063,900.00 | 1,300,730 | 2024-05-28 | Filing | |
| $20.70 | 190,000 | $3,932,734.00 | 1,100,730 | 2024-02-21 | Filing | |
| $21.61 | 120,409 | $2,602,038.49 | 910,730 | 2023-11-27 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $42.58 | 28,043 | $1,194,070.94 | 374,029 | 2025-11-21 | Filing | |
| $41.77 | 10,648 | $444,766.96 | 0 | 2025-11-20 | Filing | |
| $41.93 | 23,539 | $986,990.27 | 0 | 2025-11-20 | Filing | |
| $42.11 | 10,000 | $421,100.00 | 402,072 | 2025-11-20 | Filing | |
| $43.55 | 100,000 | $4,355,000.00 | 1,189,228 | 2025-11-12 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 29,366,959 | $1,212,855,422 | 0.02% | |
| 2. | 26,064,571 | $1,076,466,783 | 0.02% | |
| 3. | 11,114,815 | $459,041,860 | 0.02% | |
| 4. | 8,320,794 | $343,648,794 | 1.17% | |
| 5. | 7,670,959 | $316,847,900 | 0.02% |
News See All
Exelixis, Inc. (EXEL) Gets Upgraded to Outperform from Market Perform by Leerink Partners
Exelixis, Inc. (NASDAQ:EXEL) is one of the most profitable biotech stocks to buy. On October 21, Exelixis, Inc. (NASDAQ:EXEL) got upgraded to Outperform from Market Perform by Leerink Partners.
9 Most Profitable Biotech Stocks to Buy
On October 6, StemPoint Capital CIO Michelle Ross appeared on CNBC’s ‘Closing Bell’ to talk about the biotech space.
Exelixis (EXEL) Loses 12% on Cancer Treatment Trial Results
In an updated report, Exelixis, Inc.
Exelixis (EXEL) Rated Equalweight by Barclays Amid Cancer Drug Outlook
Exelixis, Inc. (NASDAQ:EXEL) ranks among the most undervalued NASDAQ stocks to buy now. On September 17, Barclays began coverage of Exelixis, Inc.
Morgan Stanley Maintains Overweight Rating For Exelixis, Inc. (EXEL), Price Target Raised To $50
Exelixis, Inc. (NASDAQ:EXEL) is among the Renaissance Technologies Portfolio: 10 Biggest Stocks.
14 Most Undervalued NASDAQ Stocks to Buy Now
On September 22, stocks surged to mark a third consecutive day of record-high closes, driven by hopes that the AI trade and additional Fed policy easing would boost the upward trend.
Renaissance Technologies Portfolio: 10 Biggest Stocks
The American quant hedge fund is known for using statistical and mathematical tools to drive its investment programs.
Exelixis Appoints Longtime Veteran Dana T. Aftab as Head of R&D
Exelixis Inc. (NASDAQ:EXEL) is one of the best growth stocks to buy for the next 2 years. On August 29, Exelixis Inc. announced the appointment of Dana T.
Exelixis, Inc. (EXEL): A Bull Case Theory
We came across a bullish thesis on Exelixis, Inc. on Investing With Purpose’s. In this article, we will summarize the bulls’ thesis on EXEL.